S-1: United Health Products Files for Resale of 15 Million Common Shares by White Lion Capital

United Health Products seeks to register the resale of 15 million common shares by White Lion Capital, aiming to fulfill obligations under their Common Stock Purchase Agreement.

Summary

• United Health Products, Inc. (UHP) has filed a registration statement for the resale of up to 15,000,000 shares of its common stock by White Lion Capital, LLC.
• These shares are related to the Common Stock Purchase Agreement (CSPA) between UHP and White Lion, where White Lion has committed to potentially purchase up to $10,000,000 of UHP's common stock.
• As of the prospectus date, UHP has sold 14,240,000 shares to White Lion under a prior registration, generating approximately $3,000,000 in gross proceeds, leaving $7,000,000 worth of shares available for future sales.
• The selling security holder may sell shares at fixed, prevailing market, varying, or negotiated prices on otcmarkets.com or in private transactions.
• UHP will not receive proceeds from the resale of shares by White Lion, but may receive proceeds from the sale of shares to White Lion under the CSPA.
• The company's common stock is currently quoted on the OTCMarkets platform under the symbol UEEC, with a last sale price of $0.153 per share on June 24, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's potential funding through White Lion, the company faces significant financial challenges, including operating losses, going concern doubts, and market competition. The reliance on a single product and regulatory hurdles further dampen the outlook.

Positives

• The CSPA provides a potential source of funding for UHP, with White Lion committed to purchasing up to $10,000,000 of common stock.
• UHP has already received approximately $3,000,000 from White Lion, demonstrating the agreement's functionality.
• The company's hemostatic gauze technology is protected through patents granted by the U.S. Patent and Trademark Office, which protection currently runs through 2029.

Negatives

• UHP will not receive any proceeds from the resale of shares by White Lion.
• The market price of UHP's stock has been and may continue to be highly volatile.
• The low trading volume of UHP's common stock may adversely affect the price of the shares and their liquidity.
• The company has a history of operating losses and may continue to lose money in the future.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The market price of UHP's stock is highly volatile.
• Low trading volume may adversely affect the stock price and liquidity.
• Future equity offerings could dilute the common stock.
• Sales of a significant number of shares could depress the market price.
• UHP does not intend to pay cash dividends in the foreseeable future.
• There is currently no established market for UHP's common stock.
• UHP's common stock is deemed a penny stock, which may make it more difficult for investors to sell their shares.
• UHP has a history of operating losses and may continue to lose money.
• There is no assurance that the Class III application for internal surgical procedures will be approved by the FDA.
• There is no assurance that ongoing discussions with potential commercial partners and acquirers will result in a specific transaction.
• UHP will need additional financing to execute its business plan and fund operations, which may not be available.
• There is no guarantee of market acceptance of UHP's hemostatic gauze products.
• UHP may be dependent upon commercial relationships to conduct its operations and implement its strategy.
• UHP could experience difficulties in its supply chain.
• UHP is currently dependent on one hemostatic gauze product to generate income in the future.
• UHP's business may suffer if it does not attract and retain talented personnel.
• UHP may not be able to adequately protect its technologies or intellectual property rights.
• UHP has identified various material weaknesses in its internal control over financial reporting.
• UHP's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The healthcare industry is subject to extensive government regulation.
• Failure to comply with laws or government regulations could result in penalties.
• UHP is subject to the reporting requirements of the federal securities laws, which can be expensive.
• Public company compliance requirements may make it more difficult to attract and retain officers and directors.
• Offers or availability for sale of a substantial number of shares of UHP's common stock may cause the price of its common stock to decline.

Future Outlook

The company is evaluating paths to rapidly grow revenue and profits in all potential market segments, with the objective of maximizing shareholder value. Options under consideration include a sale or merger of the Company with an industry leader or one or more commercial partnerships with established market participants.

Industry Context

The wound care products market is concentrated among large, established companies such as Baxter International, Becton Dickinson & Company, Bristol-Myers Squibb Company, Johnson & Johnson, and 3M Company, each of which has greater capital and operational resources than UHP.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards in terms of financial performance or operational metrics.
• It acknowledges that the wound care market is dominated by large, established companies with significantly greater resources, such as Baxter International, Johnson & Johnson, and 3M.
• Without specific data, it's difficult to assess UHP's performance against industry benchmarks.

Stakeholder Impact

• Shareholders face risks related to stock volatility, dilution, and the company's ability to continue as a going concern.
• Employees' job security is uncertain due to the company's financial challenges.
• Customers may face uncertainty regarding the availability of the company's products.
• Suppliers may face risks related to the company's ability to pay its obligations.
• Creditors face risks related to the company's ability to repay its debts.

Next Steps

• The company will continue to work towards obtaining FDA Class III approval for its hemostatic gauze product.
• The company will continue to evaluate potential commercial partnerships and strategic alternatives, including a sale or merger.
• The company may issue purchase notices to White Lion Capital under the CSPA, subject to certain limitations and conditions.

Key Dates

Keywords

Common Stock, White Lion Capital, Resale, Hemostatic Gauze, Premarket Approval, FDA, CSPA, UEEC, United Health Products, Offering